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a b s t r a c t
Introduction: Atherosclerosis is the main cause of mortality in the Czech Republic. In our
previous cross-sectional studies, we detected a high prevalence of metabolic cardiovascular
risk factors in women before and after menopause and found menopausal transition to be
critical period for atherosclerosis acceleration. In the present longitudinal study, we studied
changes of main cardiovascular risk factors in women after transition to menopause.
Methods: We analyzed data of 195 women who became menopausal and 292 women who
stayed in menopause during 6-year period. The cardiovascular risk factors under study were
as follows: smoking, body mass index, waist circumference, blood pressure, plasma lipids
including apolipoprotein B and A1 and fasting glycemia.
Results: The most striking differences between newly and steadily menopausal women were
found in changes of plasma lipids. With the exception of HDL cholesterol all changes were
less favorable in newly menopausal women and were not associated with treatment with
statins. No signiﬁcant differences between both groups were found for changes in body mass
index, waist circumference, blood pressure and fasting glycemia.
Conclusions: In longitudinal study we conﬁrmed that time around menopausal transition is
one of the most dynamic periods regarding changes of cardiovascular risk factors, mainly
plasma lipids.
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Cardiovascular disease caused by atherosclerosis is the main
cause of mortality among men and women in developed
countries including the Czech Republic [1]. Although cardio-
vascular disease caused by atherosclerosis is rare in premen-
opausal women, the incidence steeply increases after
menopause. Unresolved issue remains if these changes are
caused rather by chronological aging or by menopause
accompanied by decrease in the estrogen concentration. If
the latter is correct, the change of cardiovascular risk factors
around menopause could be critical for the development of
atherosclerosis and its complications [2,3]. Despite increasing
interest in menopausal transition and evidence that it is really
atherogenic [4,5], only general recommendations were recent-
ly published focused on this period in woman's life [6,7] and
only sparse data from reliable longitudinal studies are
available [2,3].
In our previous work, we detected a high prevalence of
metabolic cardiovascular risk factors in women before and
after menopause [8,9]. In addition, we found menopausal
status as a risk factor for the development of hypertension,
though potentially mediated through increased body mass
index [10]. We also found that menopausal transition could be
a critical period for atherosclerosis acceleration under certain
conditions, namely smoking [11]. The impact of menopausal
transition could be mediated through several mechanisms
including impaired vascular protection, impaired reverse
cholesterol transport, and impaired balance of sex hormones
[11]. In a recent longitudinal study, we studied changes of main
cardiovascular risk factors after transition to menopause.
Materials and methods
Population
The study was already described in detail elsewhere [8–11]. In
short, the Prague Pre and Post Menopausal Female (3PMFs)
study is based on a 5% representative and random sample of
women aged 45–54 years living in Prague recruited in 2003. In
2004–2006, 908 women underwent baseline examination. All
women throughout the study reported their ﬁnal menstrual
period (FMP) on a monthly basis. For deﬁnition of reproductive
status, we used criteria proposed by the ‘‘Stages of Reproduc-
tive Aging Workshop’’ (STRAW) [12] together with levels of
follicle stimulating hormone (FSH). According to this, women
were divided into 3 groups: premenopausal, when the FMP was
reported in within 61 days before the interview; perimen-
opausal, if the FMP was reported 61–365 days before the
interview; and postmenopausal, when the FMP was reported
more than 365 days before the interview. The second
examination was performed after 5.7  0.8 years. Complete
data were obtained in 676 women. In this analysis we focused
on 303 newly menopausal women and on 292 steadily
menopausal women as controls.
The deﬁnition of newly menopausal women was as follows:
reported FMP within 61 days before baseline examination with
level of FSH lower than 40 IU/L and reported FMP more than365 days before the second examination with levels of FSH
more than 40 IU/L. The deﬁnition of steadily menopausal
women was as follows: reported FMP more than 365 days
before the ﬁrst and second examination with levels of FSH
more than 40 IU/L at both examinations. After exclusion of
women after hysterectomy/ovariectomy and of women using
hormone replacement therapy the study group comprised 195
newly menopausal women and control group comprised 292
steadily menopausal women. The ethics committee of the
Institute a priori approved the whole study, and all partici-
pants provided their signed informed consent for the second
examination.
Anthropometric and laboratory variables
All participants were interviewed about their medical history
and main cardiovascular risk factors. Height, weight, waist
circumference and blood pressure were measured according to
the WHO MONICA (‘‘monitoring trends and determinants in
cardiovascular disease’’) protocol [13,14]. Body mass index was
calculated as weight in kg divided by squared height in meters.
Women with a history of current and past regular smoking
were deﬁned as smokers. Systolic and diastolic blood
pressures were measured in the right arm with the subject
in the sitting position after at least ten minutes at rest. Three
blood pressure measurements were obtained, and the mean
value of the last two measurements was used for further
analyses. Blood samples were drawn after overnight fasting.
Serum total cholesterol and triglycerides were measured using
the fully automated (HITACHI 911 Auto Analyzer, Japan)
enzymatic method (reagents from Hoffmann, La Roche, Basel,
Switzerland). HDL-cholesterol was determined using the same
method after precipitation of serum lipoproteins with sodium
phosphotungstate and magnesium chloride kits. Serum LDL
cholesterol was measured using an automated method with
direct determination using an LDL-C plus kit from Hoffmann-
LaRoche (Basel, Switzerland). FSH was measured using IRMA
kits (Immunotech, Prague, Czech Republic). Fasting glycemia
was determined enzymatically (Lachema, Brno, Czech Repub-
lic).
Data analysis
Data are presented as percentages for categorical variables and
means for continuous variables. Between-group comparison
of continuous variables was performed using unpaired t-test.
Paired t-test was used for the detection of changes of
cardiovascular risk factors in the case of continuous variables.
The x2 test was applied for discrete variables. Between-group
comparisons of mean change of particular covariates were
performed using unpaired t-test.
Results
At the baseline examination age and FSH levels were
signiﬁcantly lower in newly menopausal women than in
steadily menopausal women; the same was found for waist
circumference, LDL cholesterol, and apolipoprotein B. No
signiﬁcant differences were found in body mass index, blood
Table 1 – Baseline values of cardiovascular risk factors in Prague Pre and Post Menopausal Female study.
Women newly
menopausal
n = 195
Women steadily
menopausal
n = 292
p for difference between
newly and steadily menopausal women
Age (years) 48.87 (2.51) 51.66 (2.17) <0.0001
Follicle stimulating hormone (IU/L) 18.02 (19.38) 73.42 (38.00) <0.0001
Body mass index (kg m2) 25.24 (4.18) 25.79 (4.77) 0.19
Waist circumference (cm) 84.55 (11.05) 87.51 (12.90) 0.009
Systolic blood pressure (mm Hg) 118.32 (15.68) 118.01 (15.69) 0.831
Diastolic blood pressure (mm Hg) 78.66 (10.05) 78.44 (9.65) 0.809
LDL cholesterol (mmol/L) 3.31 (0.82) 3.62 (0.79) <0.0001
HDL cholesterol (mmol/L) 1.61 (0.38) 1.64 (0.38) 0.394
Triglycerides (mmol/L) 1.29 (0.60) 1.34 (0.72) 0.423
Apolipopoprotein B (g/L) 1.00 (0.23) 1.08 (0.25) 0.002
Apolipopoprotein A1 (g/L) 1.64 (0.268) 1.64 (0.25) 0.933
Fasting glycemia (mmol/L) 5.11 (0.49) 5.16 (0.65) 0.361
Values are expressed as mean (SD).
Table 2 – Change in smoking habits after 6 years in Prague Pre and Post Menopausal Female study.
Women newly menopausal Women steadily menopausal
Non-smokers Past-smokers Current smokers Non-smokers Past-smokers Current smokers
Baseline examination 107 (54.9) 36 (18.5) 46 (23.6) 142 (48.8) 51 (17.5) 89 (30.6)
Follow-up examination 110 (56.4) 44 (22.6) 37 (19.0) 141 (48.3) 66 (22.6) 76 (26.0)
p for difference between
ﬁrst and second
examination (x2)
0.412 0.212
Values are expressed as numbers (%); in newly menopausal women two intermittent smokers were not included at the baseline visit in the
analysis, in steadily menopausal women one intermittent smoker was not included.
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and glycemia (Table 1).
Regarding changes of smoking habits at the second
examination in both groups of women, there was moderate
decrease of current smokers. However, these differences were
not signiﬁcant both within each group and between groups
(Table 2).Table 3 – Changes in cardiovascular risk factors under study in
Women newly
menopausal
n = 195
Follicle stimulating hormone (IU/L) 60.14 (37.5)***
Body mass index (kg m2) 1.36 (2.19)***
Waist circumference (cm) 2.51 (7.37)***
Systolic blood pressure (mm Hg) 9.78 (15.71)***
Diastolic blood pressure (mm Hg) 2.06 (9.29)***
LDL cholesterol (mmol/L) 0.08 (0.88) 
HDL cholesterol (mmol/L) 0.07 (0.29) 
Triglycerides (mmol/L) 0.13 (0.67)*
Apolipopoprotein B (g/L) 0.04 (0.26) 
Apolipopoprotein A1 (g/L) 0.04 (0.27) 
Fasting glycemia (mmol/L) 0.278 (0.58)***
Treatment with statins, n (%)y 10 (5.0) 
Anihypertensive treatment, n (%)y 49 (25.1) 
Values are expressed as mean of difference (SD) if not stated differently
* p < 0.05.
** p < 0.01.
*** p < 0.001.
y Data from the second visit.Changes of other cardiovascular risk factors under study are
presented in Table 3. Body mass index and waist circumference
signiﬁcantly increased both in newly and steadily menopausal
women; the increase was moderately higher in newly meno-
pausal women, especially waist circumference; however,
no statistically signiﬁcant differences between groups were
observed. Systolic blood pressure increased to a similar extent in Prague Pre and Post Menopausal Female study.
Women steadily
menopausal
n = 292
p for difference between
newly and steadily
menopausal women
8.04 (34.4)*** <0.0001
1.12 (2.08)*** 0.228
1.28 (8.03)*** 0.09
7.34 (16.08)*** 0.10
0.79 (10.40) 0.17
0.300 (0.90)*** <0.0001
0.001 (0.29) 0.01
0.04 (0.63) 0.004
0.03 (0.27)** 0.002
0.08 (0.24)** 0.09
0.28 (0.99)*** 0.971
29 (9.5) 0.09
93 (31.8) 0.007
; change from the baseline values inside each group.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 1 3 – e 1 1 7e116both groups, diastolic blood pressure increased signiﬁcantly in
newly, but not in steadily menopausal women; however, the
difference of changes of blood pressure was not signiﬁcant
between both groups. The most divergent results in both groups
were observed in changes of lipid parameters. In newly
menopausal women no signiﬁcant changes of LDL, HDL
cholesterol, apolipoprotein B and apolipoprotein A1 were
detected; however, levels of plasma triglycerides signiﬁcantly
increased. In contrast, in steadily menopausal women, LDL
cholesterol and apolipoprotein B signiﬁcantly decreased, while
no signiﬁcant changes of plasma HDL cholesterol and plasma
triglycerides were observed. Changes of all lipid parameters
were signiﬁcantly different between newly and steadily
menopausal women with the exception of apolipoprotein A1,
in which case this difference was only of borderline signiﬁcance.
Fasting glycemia increased signiﬁcantly and almost identically
in both groups of women. Five percent of newly menopausal
and ten percent of steadily menopausal women were treated by
statins. This difference was not statistically signiﬁcant. When
women treated with statins were excluded from the analysis no
substantial changes in results were detected. Signiﬁcantly
higher prevalence in antihypertensive treatment was found in
steadily menopausal women. Exclusion of women with
antihypertensive treatment did not signiﬁcantly modify differ-
ences in changes of factors under study between newly and
steadily menopausal women.
Discussion
In the population-based longitudinal study we detected that
after transition to menopause the most robust increase was
observed in body mass index, waist circumference, fasting
glycemia and plasma triglycerides. In addition, the most
striking differences between newly menopausal women and
steadily menopausal women were found for changes in LDL
cholesterol, apolipoprotein B, plasma triglycerides and HDL
cholesterol after 6 years. With the exception of HDL cholester-
ol, all detected plasma lipid changes were less favorable in
newly menopausal women and were not associated with
treatment with statins. No signiﬁcant differences between
groups were observed for body mass index, waist circumfer-
ence, blood pressure, and fasting glycemia.
Although many studies investigated reproductive status
and the impact of various hormones on atherosclerosis, many
controversies remain. On one hand, the age at menopause was
not detected as an additional predictor of subclinical athero-
sclerosis and/or coronary events [15,16]. On the other hand
there is evidence that menopause and rate of changes during
menopausal transition could be of importance in cardiovas-
cular risk burden and atherosclerosis development [17,18].
However, the changes during menopausal transition could be
complex and could mirror actual disequilibrium between
deleterious and protective mechanisms. It had been known
that natural menopause is associated with increase in all
cardiovascular risk factors. Nevertheless, it is difﬁcult to
differentiate if changes of cardiovascular risk factors are
caused by chronological aging or by menopause. Even from
longitudinal studies the answer is not obvious, because there
is problem to ﬁnd appropriately matched controls. In our studywe used as a control group steadily menopausal women from
the same population in contrast to other studies, where
premenopausal women of the same age were included as a
control population. In addition, we measured changes of
follicle stimulating hormone in both visits to differentiate
between chronological and ovarian aging.
The most interesting results were observed in plasma
lipids. Changes in plasma lipids were already described in
longitudinal studies including thousands of participants. One
of the most reliable is longitudinal SWAN study [2,3]. In this
study, in 541 healthy and initially premenopausal women
changes in lipid factors were established after 2–3 years. Age-
matched premenopausal women comprised control group. In
women with history of natural menopause and did not receive
hormone-replacement therapy, serum levels of high-density
lipoprotein (HDL) cholesterol declined more than in controls,
and plasma LDL cholesterol increased. In contrast, natural
menopause did not have any impact on blood pressure,
plasma glucose, insulin levels, and body weight.
In our study we observed quite similar ﬁndings, with the
exception of non-signiﬁcant increase of HDL cholesterol in
newly menopausal women, and its decrease in steadily
menopausal women. These differences could be caused by
different control group which comprised steadily menopausal
women and also by longer time interval after menopause in
our study compared to SWAN (5.7 vs. 2.5 years). For signiﬁcant
and robust decline in LDL cholesterol in steadily menopausal
women we have no reliable explanation. When looking at
crude available data in this study regarding changes in lifestyle
(smoking, physical activity, basic dietary habits) we have not
found any signiﬁcant difference between newly and steadily
menopausal women. One of the speculative explanations is
the overall trend for decrease of LDL cholesterol in the whole
Czech population [19], which was reﬂected in ‘‘stable’’
population of steadily menopausal women, but not in
‘‘dynamically changing’’ population of newly menopausal
women.
Regarding another robust independent cardiovascular risk
factor – blood pressure – we observed increase in systolic and
diastolic blood pressures in both groups. While in newly
menopausal women this increase was signiﬁcant for both –
systolic and diastolic pressure, in steadily menopausal women
only systolic blood pressure increased signiﬁcantly. Neverthe-
less, the difference in change in diastolic blood pressure was
not signiﬁcant between both groups and could be attributed to
more frequent antihypertensive treatment in steadily post-
menopausal women or to chance ﬁnding. In general, we
observed the same situation as in already published studies –
after menopause the values of systolic and diastolic blood
pressure are increasing and are associated with increased
prevalence of hypertension in women at older age.
Limitations of our study are only two examinations
completed in period of almost 6 years with the lack of more
frequent follow-up up and thus the absence of more detailed
description of transition to menopause. However, striking
difference in the increase of FSH between newly and steadily
menopausal women reﬂects rather ovarian than chronological
aging in the study group.
The strengths of our study are population-based approach
with a well-deﬁned reproductive status and its changes
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design. In addition, we believe, that steadily menopausal
women are more relevant control group when detecting
changes of cardiovascular risk factors in menopausal
transition.
In conclusion, our results suggest that natural menopause
has an unfavorable effect on lipid metabolism, which may
contribute to robust increase in the risk of coronary disease
after this period. In addition, we conﬁrmed our previous
ﬁndings, that menopausal transition is unique dynamic period
in woman's life accompanied by robust changes of cardiovas-
cular risk factors, mainly plasma lipids. If these results are
conﬁrmed, transition to menopause could be the best period
for complex intervention of cardiovascular risk factors
including plasma lipids.
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